Skip Navigation


JAC Advance Access originally published online on January 16, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/2/149    most recent
dkh068v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Muller-Serieys, C.
Right arrow Articles by Cantalloube, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muller-Serieys, C.
Right arrow Articles by Cantalloube, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 149-157
© 2004 The British Society for Antimicrobial Chemotherapy

Review

Tissue kinetics of telithromycin, the first ketolide antibacterial

C. Muller-Serieys1,*, J. Andrews2, F. Vacheron3 and C. Cantalloube3

1 Hôpital Bichat Claude Bernard, 75877 Paris Cedex 18; 3 Aventis, Romainville Cedex, France; 2 City Hospital Birmingham, Birmingham, UK

Received 22 July 2003; returned 9 September 2003; revised 3 November 2003; accepted 13 November 2003

The potential efficacy of an antibacterial depends not only on its spectrum of activity but also on its concentration at the site of infection. The tissue kinetics of telithromycin—the first ketolide antibacterial—are reviewed here. Telithromycin accumulates rapidly in white blood cells, inflammatory fluid, and cells and tissues of the upper and lower respiratory tract, with mean concentrations above the MICs of key respiratory pathogens. Tissue kinetics of telithromycin support facilitated delivery to the site of infection, good efficacy against intracellular respiratory pathogens and respiratory pathogens at extracellular sites in the airways, and effectiveness in the treatment of upper and lower respiratory tract infections (RTIs). The tissue kinetics profile of telithromycin, together with its microbiological profile, makes it a promising new antibacterial for the treatment of community-acquired RTIs.

Keywords: antibacterial, ketolide, telithromycin, tissue kinetics

* Corresponding author. Tel: +33-1-40-25-85-06; Fax: +33-1-40-25-88-52; E-mail: claudette.muller{at}bch.ap-hop-paris.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
C. Lippert, S. Gbenado, C. Qiu, B. Lavin, and S. J. Kovacs
The Bioequivalence of Telithromycin Administered Orally as Crushed Tablets Versus Tablets Swallowed Whole
J. Clin. Pharmacol., September 1, 2005; 45(9): 1025 - 1031.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Bosnar, Z. Kelneric, V. Munic, V. Erakovic, and M. J. Parnham
Cellular Uptake and Efflux of Azithromycin, Erythromycin, Clarithromycin, Telithromycin, and Cethromycin
Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2372 - 2377.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. G. Zhanel, C. Johanson, N. Laing, T. Hisanaga, A. Wierzbowski, and D. J. Hoban
Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (mefE)-Producing Macrolide- Resistant Streptococcus pneumoniae for Which Telithromycin MICs Vary
Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1943 - 1948.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
N. Kasbekar and P. S. Acharya
Telithromycin: The first ketolide for the treatment of respiratory infections
Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 905 - 916.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
T. S. Kuehnel, C. Schurr, K. Lotter, and F. Kees
Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis
J. Antimicrob. Chemother., April 1, 2005; 55(4): 591 - 594.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.